From Injections to Innovation – Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod® 5 in Adults and Children with Type 1 Diabetes
Insulet (NASDAQ: PODD) will present results from its multinational RADIANT trial at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in March 2025. The study compared the Omnipod 5 Automated Insulin Delivery System to multiple daily injections in type 1 diabetes patients aged 4-70 years across France, UK, and Belgium.
The RADIANT trial marks two significant firsts: it's the first randomized controlled trial examining direct transition from multiple daily injections to an automated insulin delivery system, and the first to assess an AID system with Abbott FreeStyle Libre 2 sensors. Results will be presented at a symposium featuring renowned medical experts, including Dr. Emma Wilmot, Dr. Chantal Mathieu, and Dr. Brynn Marks.
The conference will showcase 11 presentations and posters on Omnipod 5 and Omnipod DASH systems, covering various aspects including real-world outcomes, comparative studies, and specific use cases in both Type 1 and Type 2 diabetes patients.
Insulet (NASDAQ: PODD) presenterà i risultati del suo studio multinazionale RADIANT durante la 18ª Conferenza Internazionale sulle Tecnologie Avanzate e i Trattamenti per il Diabete (ATTD) a marzo 2025. Lo studio ha confrontato il Sistema di Somministrazione Automatica di Insulina Omnipod 5 con le iniezioni multiple giornaliere in pazienti con diabete di tipo 1 di età compresa tra i 4 e i 70 anni in Francia, Regno Unito e Belgio.
Il trial RADIANT segna due importanti primati: è il primo studio controllato randomizzato che esamina la transizione diretta dalle iniezioni multiple giornaliere a un sistema di somministrazione automatica di insulina e il primo a valutare un sistema AID con sensori Abbott FreeStyle Libre 2. I risultati saranno presentati in un simposio che vedrà la partecipazione di rinomati esperti medici, tra cui il Dr. Emma Wilmot, la Dr. Chantal Mathieu e il Dr. Brynn Marks.
La conferenza presenterà 11 presentazioni e poster sui sistemi Omnipod 5 e Omnipod DASH, coprendo vari aspetti tra cui risultati nel mondo reale, studi comparativi e casi d'uso specifici in pazienti affetti sia da diabete di tipo 1 che di tipo 2.
Insulet (NASDAQ: PODD) presentará los resultados de su ensayo multinacional RADIANT en la 18ª Conferencia Internacional sobre Tecnologías Avanzadas y Tratamientos para la Diabetes (ATTD) en marzo de 2025. El estudio comparó el Sistema de Administración Automática de Insulina Omnipod 5 con inyecciones diarias múltiples en pacientes con diabetes tipo 1 de 4 a 70 años en Francia, Reino Unido y Bélgica.
El ensayo RADIANT marca dos importantes primicias: es el primer ensayo controlado aleatorizado que examina la transición directa de inyecciones diarias múltiples a un sistema de administración automática de insulina, y el primero en evaluar un sistema AID con sensores Abbott FreeStyle Libre 2. Los resultados se presentarán en un simposio con destacados expertos médicos, incluyendo a la Dra. Emma Wilmot, la Dra. Chantal Mathieu y el Dr. Brynn Marks.
La conferencia contará con 11 presentaciones y carteles sobre los sistemas Omnipod 5 y Omnipod DASH, abarcando diversos aspectos, incluidos resultados del mundo real, estudios comparativos y casos de uso específicos en pacientes con diabetes tipo 1 y tipo 2.
인슐렛 (NASDAQ: PODD)은 2025년 3월에 열리는 제18회 국제 고급 기술 및 당뇨병 치료 회의(ATTD)에서 다국적 RADIANT 시험 결과를 발표할 예정입니다. 이 연구는 프랑스, 영국 및 벨기에의 4세에서 70세 사이의 제1형 당뇨병 환자들을 대상으로 Omnipod 5 자동 인슐린 전달 시스템과 다회 주사를 비교했습니다.
RADIANT 시험은 두 가지 중요한 첫 번째를 기록합니다: 다회 주사에서 자동 인슐린 전달 시스템으로의 직접 전환을 조사한 최초의 무작위 대조 시험이며, Abbott FreeStyle Libre 2 센서와 함께 AID 시스템을 평가한 첫 번째입니다. 결과는 Emma Wilmot 박사, Chantal Mathieu 박사, Brynn Marks 박사와 같은 저명한 의료 전문가들이 참석하는 심포지엄에서 발표될 것입니다.
이번 회의에서는 Omnipod 5 및 Omnipod DASH 시스템에 대한 11개의 발표 및 포스터가 전시되며, 실제 결과, 비교 연구 및 제1형 및 제2형 당뇨병 환자에 대한 특정 사용 사례를 포함한 다양한 측면을 다룰 것입니다.
Insulet (NASDAQ: PODD) présentera les résultats de son essai multinational RADIANT lors de la 18e Conférence Internationale sur les Technologies Avancées et les Traitements pour le Diabète (ATTD) en mars 2025. L'étude a comparé le Système de Livraison Automatique d'Insuline Omnipod 5 à des injections quotidiennes multiples chez des patients diabétiques de type 1 âgés de 4 à 70 ans en France, au Royaume-Uni et en Belgique.
L'essai RADIANT marque deux premières importantes : c'est le premier essai contrôlé randomisé examinant la transition directe des injections quotidiennes multiples à un système de livraison automatique d'insuline, et le premier à évaluer un système AID avec des capteurs Abbott FreeStyle Libre 2. Les résultats seront présentés lors d'un symposium mettant en vedette des experts médicaux renommés, notamment le Dr Emma Wilmot, le Dr Chantal Mathieu et le Dr Brynn Marks.
La conférence présentera 11 présentations et affiches sur les systèmes Omnipod 5 et Omnipod DASH, couvrant divers aspects, y compris les résultats du monde réel, les études comparatives et des cas d'utilisation spécifiques chez les patients diabétiques de type 1 et de type 2.
Insulet (NASDAQ: PODD) wird die Ergebnisse seiner multinationalen RADIANT-Studie auf der 18. Internationalen Konferenz über fortschrittliche Technologien und Behandlungen für Diabetes (ATTD) im März 2025 präsentieren. Die Studie verglich das Omnipod 5 Automatisches Insulin-Abgabesystem mit mehrfachen täglichen Injektionen bei Typ-1-Diabetes-Patienten im Alter von 4 bis 70 Jahren in Frankreich, Großbritannien und Belgien.
Die RADIANT-Studie markiert zwei bedeutende Premieren: Es ist die erste randomisierte kontrollierte Studie, die den direkten Übergang von mehrfachen täglichen Injektionen zu einem automatisierten Insulinabgabesystem untersucht, und die erste, die ein AID-System mit Abbott FreeStyle Libre 2-Sensoren bewertet. Die Ergebnisse werden auf einem Symposium präsentiert, das renommierte Mediziner umfasst, darunter Dr. Emma Wilmot, Dr. Chantal Mathieu und Dr. Brynn Marks.
Die Konferenz wird 11 Präsentationen und Poster zu den Omnipod 5- und Omnipod DASH-Systemen zeigen, die verschiedene Aspekte abdecken, einschließlich Ergebnisse aus der realen Welt, vergleichende Studien und spezifische Anwendungsfälle bei Patienten mit Typ-1- und Typ-2-Diabetes.
- None.
- None.
The study assessed changes in HbA1c as well as time in target glucose range (TIR) for people aged 4 to 70 years living with type 1 diabetes in
The RADIANT results will be discussed at an Insulet-sponsored symposium, “Transform Your Clinical Care with Omnipod 5: Revolutionizing Diabetes Management,” being held on Wednesday, March 19 from 2:40 p.m. – 4:10 p.m. CET in Hall E.
The symposium will be presented by:
-
Dr. Emma Wilmot, PhD, FRCP, Associate Professor, University of
Nottingham , School of Medicine,Nottingham, U.K. – Omnipod 5 Delivers Transformative Glycemic Outcomes – Sharing the Latest Breaking Results -
Dr. Chantal Mathieu, MD, PhD, Professor of Medicine, Katholieke Universiteit Leuven,
Belgium – How Omnipod 5 is Providing an Unparalleled User Experience -
Dr. Brynn Marks, MD, MSHPEd, Director of Technology and Attending Physician, Children’s Hospital of
Philadelphia , Assistant Professor, CE Perelman School of Medicine of the University ofPennsylvania ,U.S. – Accelerating AID for All – Reaching the Broadest Populations Effectively - Dr. Trang Ly, MBBS, FRACP, PhD, Insulet Senior Vice President and Chief Medical Officer, will provide a Company update on future innovations at the symposium
Additionally, Dr.
Oral Presentations
Thursday, March 20
Oral Presentation SO031 (4:15 p.m. – 4:20 p.m., Station 04, Session 09) – How Do Outcomes with the Omnipod 5 Automated Insulin Delivery (AID) System Compare for Persons with Type 1 Versus Type 2 Diabetes? Learnings Across Studies with Dr. Viral Shah
Oral Presentation SO034 (4:30 p.m. – 4:35 p.m., Station 04, Session 09) – Simplified Meal Bolus Strategies for the Omnipod 5 Automated Insulin Delivery (AID) System in People with Type 2 Diabetes (T2D): Sub-Analysis of the SECURE-T2D Study with Dr. Georgia Davis
Friday, March 21
Oral Presentation SO058 (4:50 p.m. – 4:55 p.m., Station 02, Session 16) – Real-World HbA1c Following Initiation of the Omnipod 5 Automated Insulin Delivery System with Dr. Carol Levy
Oral Presentation SO060 (5:00 p.m. – 5:05 p.m., Station 02, Session 16) – Real-World Glycemic Outcomes of >19,100 Adults with Type 2 Diabetes (T2D) Using the Omnipod 5 Automated Insulin Delivery (AID) System with Cloud-Based Data Management with Dr. Eden Miller
Saturday, March 22
Oral Presentation OP046 (10:50 a.m. – 11:00 a.m., Hall D1, Session 06) – Efficacy of the Omnipod 5 Automated Insulin Delivery (AID) System Compared with Multiple Daily Injections in Type 1 Diabetes: A Multinational Randomized Controlled Trial (RADIANT) with Dr. Emma Wilmot
Oral Presentation OP056 (11:30 a.m. – 11:40 a.m., Hall D1, Session 08) – Impact of Lowering Target Glucose Setting with the Omnipod 5 Automated Insulin Delivery (AID) System: Evidence from Real-World Use with Dr. Gregory Forlenza
Oral Presentation OP087 (1:45 p.m. – 1:55 p.m., Hall E, Session 13) – Improved Glycemic Outcomes with the Omnipod 5 System in People with Type 2 Diabetes Using GLP 1 – Receptor Agonists or SGLT2 Inhibitors: Sub-Analysis of the SECURE-T2D Study with Davida Kruger, NP
Poster Presentations
e-Poster PV076 – Real-World Performance of the Omnipod 5 Automated Insulin Delivery (AID) System in Adults with Type 1 Diabetes in the
e-Poster PV062 – Real-World Performance of the Omnipod 5 Automated Insulin Delivery (AID) System in Children and Adolescents with Type 1 Diabetes in the
e-Poster PV328 – Real-World Data of 13,827 French T1D Users of the Omnipod DASH Insulin Management System From a Cloud-Based Data Management Platform with Pr. Nathalie Jeandidier
e-Poster PV329 – Real-World Data of 934 French T2D Users of the Omnipod DASH Insulin Management System From a Cloud-Based Data Management Platform with Pr. Nathalie Jeandidier
Additional Exhibit Hall Activities and Programs
In the exhibition hall, delegates can look forward to a variety of interactive experiences at the Omnipod booth, showcasing how Omnipod 5 is transforming lives globally. Delivering the latest insights and learnings to audiences worldwide, attendees will have the unique opportunity to attend live recordings of the increasingly popular podcasts, Within Range: Demystifying Diabetes Tech, and the podcast specially curated for people living with diabetes, TypeCast: Life Between the Lines.
There will also be a Baird hosted webcast, “Takeaways with Dr. Trang Ly”, that recaps the highlights, new clinical data, and updates from ATTD. This will take place on Friday, March 21, 4:00 p.m. from Insulet’s exhibition booth. A link to the webcast will be available on the Investor Relations section of the Company's website at investors.insulet.com, under “Events and Presentations,” and will be archived for future replay.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in
©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. The sensor housing, FreeStyle, Libre, and related brand marks are marks of
View source version on businesswire.com: https://www.businesswire.com/news/home/20250316052311/en/
Investor Relations:
June Lazaroff
Senior Director, Investor Relations
(978) 600-7717
jlazaroff@insulet.com
Media:
Angela Geryak Wiczek
Senior Director, Corporate Communications
(978) 932-0611
awiczek@insulet.com
Source: Insulet Corporation
FAQ
What is the RADIANT trial testing for Omnipod 5 (PODD)?
When will Insulet (PODD) present the RADIANT trial results?
How many presentations about Omnipod 5 will be featured at ATTD 2025?
What makes the RADIANT trial unique for Insulet (PODD)?
Which patient populations are included in the Omnipod 5 RADIANT study?
